Kelly Thomas Patrick, CFO of Xenon Pharmaceuticals, Buys 15,000 XENE Shares at $37.32 Each

On October 1, 2026, Kelly Thomas Patrick, Chief Financial Officer of Xenon Pharmaceuticals Inc., acquired 15,000 XENE shares at $37.32 per share, totaling $559,740, as reported in the SEC Form 4 filing submitted to EDGAR.

Who is Kelly Thomas Patrick and What is Her Role at Xenon Pharmaceuticals?

Kelly Thomas Patrick serves as the Chief Financial Officer (CFO) of Xenon Pharmaceuticals, a company listed under the ticker symbol XENE. In this role, she oversees the company's financial strategy, cash management, accounting compliance, and investor relations. The CFO is directly responsible for revenue forecasts, R&D budgets, and financing decisions that can impact the stock's valuation.

As a top executive, Patrick has access to material non-public information (MNPI), including details on ongoing clinical trial results, licensing agreements, sales projections, and funding plans. This makes transparency in her securities transactions critical to preventing market abuse, as required by the SEC.

Transaction Details: 15,000 Shares at $37.32 USD Each

The recorded transaction indicates the purchase of 15,000 Xenon Pharmaceuticals shares at a per-unit price of $37.32. The transaction date, October 1, 2026, corresponds to when the CFO executed the buy order before the Form 4 filing became public. The total amount, $559,740, results from multiplying the number of shares by the per-unit price.

The SEC-mandated Form 4 must be filed within two business days of the transaction to ensure timely market access to information about insider movements, reducing information asymmetry. The official document is available on the SEC's EDGAR website (https://www.sec.gov/Archives/edgar/data/1410514/000119312526410001/0001193125-26-410001-index.htm).

Why Insiders Buy Their Own Shares – Possible Reasons

An executive may choose to buy shares for several legitimate reasons. Portfolio diversification is common; even top executives want to balance their assets between cash, real estate, and equities. Tax planning can also motivate purchases before the end of a fiscal year to optimize capital gains or take advantage of potential deductions. Personal liquidity needs, such as funding a private project or settling debt, might lead to sales, while excess liquidity could prompt purchases.

For a CFO, buying shares may reflect confidence in the company's financial trajectory, especially if revenue projections or clinical trial results are positive. However, it's important to note that purchases can also be part of an employee stock purchase plan (ESPP), without necessarily signaling a market interpretation.

How Individual Investors Monitor Form 4 Filings

Individual investors can access Form 4 filings through the SEC's EDGAR website, which offers a free search engine by company name or insider. Third-party platforms aggregate this data, offering email alerts or customized dashboards. Tools like OpenInsider, WhaleWisdom, or Bloomberg Terminal allow filtering transactions by size, type (buy or sell), and the insider's role.

It's crucial to remember that Form 4 information is limited to the declared transaction and doesn't reveal underlying motivations. Additionally, the two-day filing window means that price movements preceding the filing aren't always immediately reflected. Investors should combine Form 4 analysis with other sources, such as quarterly reports, press releases, and sector analyses, to form a more comprehensive view.